Merck & Co is discontinuing development of its adenosine A2a receptor antagonist, preladenant, for Parkinson's disease (PD) after an initial review of data from three separate Phase III trials failed to provide evidence of efficacy for the drug versus placebo.
"Based on these results, Merck is taking steps to discontinue the extension phases of these studies and no longer plans...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
